RPCEC00000370尚未招募1 期
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX - PREVAX
Center of Molecular Immunology (CIM)0 个研究点目标入组 60 人开始时间: 2021年5月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- N/a: Single Arm Study. Masking: Open. Control Group: Uncontrolled. Assignment: Single Group. Purpose: Prevention
入排标准
- 年龄范围
- 18 years 至 79 years（—）
- 性别
- All
入选标准
- •1. Patients who meet the diagnostic criteria according to the cohort to which they belong.
- •2. Patients aged = 18 years for lung cancer survivors and between 50 and 79 years for patients at high risk of lung cancer.
- •3. Patients who do not have imaging evidence of lung cancer, evaluated by CT according to RECIST criteria.
- •4. Patients of childbearing potential who consent to the use of adequate contraceptive methods (eg, hormonal or barrier methods of contraception, abstinence) before being included in the study. If a woman becomes pregnant or suspects that she is pregnant while she or her partner is participating in this study, she should inform her doctor immediately.
- •5. Patients who give their informed consent for participation in writing. In addition to the above criteria, patients must meet the following criteria specific to the cohort in which they will be included:
- •Patients at high risk of lung cancer (Cohort A).
- •1. Document the presence of any of these risk factors
- •Moderate or severe COPD.
- •Family history of lung cancer.
- •Low body mass index.
- •Recent pneumonia.
- •2. Have quit smoking in the last 10 years or be a current smoker.
- •3. Have a history of smoking at least 50 packs / year.
- •4. Have a pulmonary function test in the last 3 months before inclusion.
- •Early Stage Lung Cancer Survivors (Cohort B).
- •1. Completion of adjuvant therapy for lung cancer after surgery 3 months prior to enrollment, with no evidence of early disease progression.
- •2. NSCLC confirmed stage IB to IIIA at initial diagnosis (TNM 8th edition).
排除标准
- •1. Patients clinically unfit to undergo the bronchoscopy procedure.
- •2. Patients with uncontrolled intercurrent illnesses including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
- •3. Stage IIIA non-surgical patients.
- •4. Patients with mild or very severe COPD.
- •5. Patients with psychiatric illness and / or social situations that would limit compliance with the study requirements.
- •6. Pregnant or lactating patients.
- •7. Patients with other malignancy in the previous 5 years, except skin cancer (non-melanoma).
- •8. Patients who have received another investigational product within 30 days prior to inclusion.
- •9. Patients who have received treatment for their disease with immunotherapy.
- •10. Patients with known immunosuppressive disease (eg, HIV, AIDS, or other immunosuppressive disease). The test is not mandatory.
- •11. Patients with known hypersensitivity to the components of the vaccine under study or any analogue.
- •12. Patients requiring steroid treatment equivalent to doses greater than 20 mg of prednisone per day.
- •13. Patients reluctant or unable to follow the requirements of the protocol
研究者
相似试验
已完成
4 期
CIMAVax EGF in Lung Cancer in PHC. Phase IVon-Small Cell advanced Lung CancerRPCEC00000181Center of Molecular Immunology (CIM)1,081
尚未招募
2 期
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM)Respiratory disorders in convalescent patients from SARS-CoV-2 infectionCOVID-19SARS-CoV2Coronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusLung DiseasesRespiratory Tract DiseasesPulmonary FibrosisRPCEC00000375Center of Molecular Immunology (CIM)135
已完成
不适用
CIMAvax-EGF in Bladder canceron-muscle invasive bladder cancerUrinary Bladder NeoplasmsUrologic NeoplasmsUrogenital NeoplasmsCarcinoma in SituCarcinomaUrinary Bladder DiseasesUrologic DiseasesRPCEC00000331Center of Molecular Immunology (CIM)40
已完成
4 期
CIMAvax-EGF vaccine Predictor Phase IVAdvanced non small cell lung cancer (NSCLC)Carcinoma, Non-Small-Cell LungCarcinoma, BronchogenicBronchial NeoplasmsLung NeoplasmsRPCEC00000205Center of Molecular Immunology (CIM)
招募中
不适用
Efficacy and safety of Simeprevir/PEG alpha-IFN-2a/RBV therapy for patients with chronic hepatitis C after resection of hepatocellular carcinomaChronic hepatitis CJPRN-UMIN000012937Kansai Medical University100